Introduction: Complex cases of multiple allergies can be particularly difficult to diagnose using standard methods such as skin prick tests and assessment of a patient’s allergic history. Multiplex allergy testing may improve outcomes for allergy patients by avoiding misdiagnosis and providing reassurance. The ImmunoCAP Immuno Solid-Phase Allergen Chip (ISAC) 112 is a CE-marked, molecular, multiplex, allergy test that can test for IgE antibodies to 112 components from 51 allergen sources. However, its clinical utility is unknown and is difficult to estimate due to the complexity of the diagnostic pathway in which it is used. Objective: To assess how the ImmunoCAP ISAC 112 is currently being used in UK practice. The patient populations in which it may have the most benefit were examined, and the sequence of other tests implemented alongside ISAC was determined. Methods: A retrospective audit of 100 patient cases from 2 UK tertiary allergy clinics was performed. Fifty paediatric and fifty adult cases were selected for audit. The indications for ordering an ISAC test, the other tests used alongside ISAC, and changes in management actioned by the ISAC test were investigated. Results: 73.6% of paediatric and 78% of adult patients referred for an ISAC test were suspected to have multiple sensitizations. The sequence of testing varied greatly between cases, but 70% of adult and 98% of paediatric patients had at least one other investigation prior to an ISAC test. In most cases, ISAC testing confirmed clinical suspicion. Conclusions: A prospective research study is necessary to further investigate the clinical utility and cost-effectiveness of the ISAC. A UK national registry would be of great benefit but will require a large resource base.
Int Arch Allergy Immunol

中文翻译：

---

用于多重过敏原检测的 ImmunoCAP ISAC 112 的回顾性临床审计。

简介：使用标准方法（例如皮肤点刺试验和患者过敏史评估）诊断多种过敏的复杂病例可能特别困难。多重过敏测试可以通过避免误诊和提供安慰来改善过敏患者的预后。ImmunoCAP 免疫固相过敏原芯片 (ISAC) 112 是一种带有 CE 标志的分子式多重过敏测试，可测试针对 51 种过敏原来源的 112 种成分的 IgE 抗体。然而，它的临床效用是未知的，并且由于使用它的诊断途径的复杂性而难以估计。客观的：评估目前英国实践中如何使用 ImmunoCAP ISAC 112。检查了可能受益最大的患者群体，并确定了与 ISAC 一起实施的其他测试的顺序。方法：对来自 2 个英国三级过敏诊所的 100 例患者病例进行回顾性审核。选择了 50 例儿科病例和 50 例成人病例进行审计。对订购 ISAC 测试的指示、与 ISAC 一起使用的其他测试以及由 ISAC 测试采取的管理变化进行了调查。结果：73.6% 的儿科患者和 78% 的成人患者被怀疑有多重过敏。不同病例的检测顺序差异很大，但 70% 的成人和 98% 的儿科患者在进行 ISAC 检测之前至少进行了一项其他检查。在大多数情况下，ISAC 测试证实了临床怀疑。结论：有必要进行前瞻性研究以进一步调查 ISAC 的临床效用和成本效益。英国的国家注册将大有裨益，但需要庞大的资源基础。
Int Arch 过敏免疫